Gilead Sciences, Inc. which can be found using ticker (GILD) have now 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $119.00 and $68.50 suggesting an average Analsyt target price of $81.72. Given that the stocks previous close was at $75.13 this now indicates there is a potential upside of 8.8%. There is a 50 day moving average of $71.38 while the 200 day moving average is $73.19. The company has a market cap of 94.58B. The stock price is currently at: $75.97 USD
The potential market cap would be $102,878,106,461 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 92.65, revenue per share of $22.30 and a 11.55% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
